International journal of clinical practice
-
Int. J. Clin. Pract. · Jun 2021
Observational StudyThe Association between Micronutrient and Hemogram Values and Prognostic Factors in COVID-19 Patients: A Single Center Experience from Turkey.
The contribution of micronutrients to the immune system has been known for a long time. This study aimed to investigate the association between the micronutrient levels and hemogram values and prognostic factors of the disease in COVID-19 patients in Ankara City Hospital. ⋯ Micronutrient and hemogram values, advanced age, being male, and having comorbid diseases were correlated with the poor prognosis of COVID-19 infection. Deficiency of Iron, Folate, and vitamin D should be well-considered in COVID-19. Excessive vitamin B12 and multivitamin supplementation should be avoided by choosing supplement wisely. In addition, attention should be paid to leukocytosis, lymphocyte counts, and anemia during COVID-19 patient follow-up. What's known Some micronutrients have an immunomodulatory and anti-inflammatory effect with antioxidant effects and thus play a protective role in respiratory tract infections as COVID-19. Vitamin D deficiency is found to be associated with poor prognostic factors in COVID-19. Lymphopenia is found to be associated with poor prognostic factors in COVID-19. What's new According to the results obtained from our study, low iron and folate levels should be controlled first in patients diagnosed with COVID-19, low vitamin D levels should also be well-considered, and supplementation should be provided in the case of deficiencies. On the other hand excessive use of vitamin B12 should be avoided. The fact that all micronutrients should be evaluated and managed by choosing wisely rather than a complete multivitamin supplement approach was demonstrated by the differences in the poor prognosis levels of vitamin B12 versus the other micronutrients. In addition, it was found in our study that leukocytosis, lymphocyte counts, and anemia should be taken into consideration together when evaluating hemogram parameters in the follow-up of COVID-19 patients.
-
Int. J. Clin. Pract. · Jun 2021
Beyond Knowledge: Evaluating the Practices and Precautionary Measures towards COVID-19 among Medical Doctors in Jordan.
Health Care Workers (HCWs), including medical doctors, played a pivotal role as a first-line defence against the COVID-19 pandemic. Because of high exposure, HCWs are at an increased risk of contracting the disease. ⋯ The level of precautionary behaviour of medical doctors in Jordan was not optimal. More attention and efforts are needed to enhance the adherence of doctors to precautionary guidance. Strengthening the role of infectious disease and infection control units within healthcare settings remains a necessity.
-
Int. J. Clin. Pract. · Jun 2021
Case ReportsA case report of rhabdomyolysis caused by the use of roxadustat in the treatment of caused by renal anemia.
In this case, we share a case of one of our patients developed rhabdomyolysis after he was administered roxadustat to treat anaemia caused by chronic renal failure. ⋯ Physicians should be alert about the occurrence of rhabdomyolysis when roxadustat is used.
-
Int. J. Clin. Pract. · Jun 2021
Meta AnalysisThe efficacy of voxelotor, 900 mg in patients with sickle cell anemia: a meta-analysis of the randomized controlled trials.
Sickle cell anaemia (SCA), an inherited chronic hematological disease affecting hundreds of thousand people worldwide, causes significant morbidity and reduced life expectancy about two or three decades. This study aimed to conduct a meta-analysis of the efficacy of voxelotor, 900 mg in patients with SCA. ⋯ As a conclusion, voxelotor, 900 mg use significantly increased hemoglobin levels which of 1 g/dL elevation predicts a reduced risk of stroke (41%), albuminuria (53%), pulmonary arterial hypertension (57%), and mortality (64%) in recent studies. Voxelotor also reduced markers of hemolysis but failed to reach statistically significance in current evidence. Multicenter, randomized, placebo-controlled studies are on the way and will provide more evidence to see the potential of disease-modifying effects of voxelotor.
-
Int. J. Clin. Pract. · Jun 2021
Randomized Controlled TrialComparison of Losartan and Amlodipine Effects on the Outcomes of Patient with COVID-19 and Primary Hypertension: A Randomized Clinical Trial.
Controversy exists regarding the drug selection in hypertension (HTN) management in patients with COVID-19. This study aimed to compare the effects of losartan and amlodipine in patients with primary HTN and COVID-19. ⋯ There was no priority in losartan or amlodipine administration in COVID-19 patients with primary HTN in decreasing mortality rate, hospital and ICU length stay. Further studies need to clarify the first-line anti-HTN medications in COVID-19.